{
  "id": "75f3d8c2a48e8775",
  "title": "ILiAD secures $115m Series B to propel pertussis vax",
  "description": "20260211T171500Z",
  "content": "",
  "source": "bioxconomy.com",
  "source_url": "https://www.bioxconomy.com/investment/iliad-secures-115m-series-b-to-propel-pertussis-vax-into-phase-iii-trials",
  "published_at": "20260211T171500Z",
  "fetched_at": "2026-02-12T00:28:38.246764+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [],
  "location": "",
  "raw_data": {
    "url": "https://www.bioxconomy.com/investment/iliad-secures-115m-series-b-to-propel-pertussis-vax-into-phase-iii-trials",
    "url_mobile": "",
    "title": "ILiAD secures $115m Series B to propel pertussis vax",
    "seendate": "20260211T171500Z",
    "socialimage": "https://eu-images.contentstack.com/v3/assets/blt72fb3b8b4630b7db/blt458205ed035b7367/698c81ab3e992f0acfef76a6/Depositphotos_302800986_L.jpg?disable=upscale&fit=crop",
    "domain": "bioxconomy.com",
    "language": "English",
    "sourcecountry": ""
  }
}